Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And we also have a very strong understanding of manufacturing processes |
| So, I think there's a very, very bright future ahead for BMS |
| I'm also incredibly excited about the SystImmune Co-Promotion, Co-Development opportunity |
| we're extremely proud that BMS and specifically, Breyanzi was successful in showing that clinical benefit and look forward to the opportunity to bring this transformation to patients |
| What do you think is going to be the biggest surprise over the next five years across the oncology and cell therapy? Lynelle Hoch Let me just say, I think it's an extraordinary time for BMS as we kind of move to the next chapter of BMS, and we have an extraordinary pipeline, and we have a bevy of new products that we are launching around the world, and we're quite excited about the opportunity that presents itself in front of us |
| And I have to say as we thought going into this week and where we sit today, we are extremely confident in the discussion that we will have the FDA |
| We also know that the side effects profile is better than Revlimid, so it becomes a really important option as a maintenance therapy for patients |
| So, for us, we feel very proud of our overall portfolio |
| And so, for us, we're extraordinarily excited about the opportunity |
| And I'd say that we're extraordinarily excited about that because we've had years of experience of understanding the overall profile of our CD19 construct, both from a safety and efficacy |
| In fact, we're so excited about the data that our intention is to proceed with the Phase 3 study before the end of this year |
| We're actually excited about the results |
| And we're excited to be one of those companies that we think is well-suited to [technical difficulty] based on, as I said, the construct, the thought leader that we're working very closely with as our lead PI, as well as our deep capabilities across CAR T and autoimmune |
| And we're super excited as well that our lead PI is Georgette, which makes it even more exciting to be working with a world-renowned thought leader in this space as we accelerate our program |
| We'll be in a much better and more competitive position as we move into earlier lines |
| So, the experience and the capabilities we have in cell therapy, along with our depth of experience and understanding in autoimmune, puts CMS in a unique position to lead in this space |
| So, we do feel very, very confident on the clinical benefit that Abecma can offer into earlier lines, one, because of our pivotal study with -- showing meeting our primary endpoint of PFS, but also we made the decision to make a patient-centric approach in our trial design by [progression-free] (ph) specified crossover for the trial of KarMMa-3, which did compound the results |
| They will be exposed to multiple lines of therapy and therefore, they want to be very choiceful as you're pulling a CAR T into earlier lines, and what's the tox profile you're going to be exposing them to, and how that will impact them over the life of living with multiple myeloma? So, I do think this is why we're confident in our overall profile |
| When you look at the totality of those three instances, in addition to becoming unconstrained on vector, we really do see the opportunity to double the breast milk patient population we'll be able to reach with our best-in-class brands |
| We successfully navigated [Augtyro] (ph), which is actually the equivalent of an ODAC for Europe, and that resulted in a positive CHMP nod |
| We're in a unique position because we have a best in class CD19 construct in Breyanzi that now we have put on an optimized manufacturer process, which is now our CD19 next key program |
| I think when you think about multiple myeloma, it's a highly fragmented disease treated very different ways for those different patient populations, and we're really proud that we have multiple different types of modalities that can treat different patients' needs across the journey of multiple myeloma |
| I think most physicians are very strong on their opinion, including the community that patients need to be exposed to a CAR T |
| And we're really pleased with the results of that Phase 2 study |
| I think the promise of cell therapy and autoimmune disease is huge, but I'm also incredibly excited about our recent acquisition of RayzeBio |
| Again, we remain committed and excited about the opportunity and anemia induced by myelofibrosis |
| We also are in a unique position |
| If you just think about the line extensions here for Breyanzi and the ability to drive a continued another layer of growth |
| We expect to see continued growth, into this year and beyond for Reblozyl in the first-line setting |
| Secondly, and most importantly, is fully automating your manufacturing process end-to-end so that you actually are able to scale because you take less footprint in your manufacturing buildings when you actually are fully automated, and it actually helps you with turnaround time and speed to patient |
| Statement |
|---|
| At the same time, we've heard from peers in the space that there are sort of capacity constraints at the academic center level |
| But because of the nature of the disease and the function of the T cells, it's been very challenging for CAR Ts to have success in showing clinical benefit across efficacy and safety |
| Stock responded negatively, at least for a portion of the day |
| Certainly in terms of your longer term projections, a big part of that is the CELMoDs that are potentially going to be launching the latter half of this decade, but I think from the outside looking in, you have a lot of different pieces that potentially could fit different segments, and it's been challenging for, I think, for investors to figure out, okay, well, this asset's going to go there, this asset's going to go there |
| In terms of competitive threat from bispecifics here, how do you how do you see that? We've heard again noise from peers that they're sort of dipping at the heels |
| But we also saw growth in RS negative |
| So, I do think our profile will work harder for us |
| Carter Gould I guess one of the other questions we get all the time is, given we've seen the challenges in oncology, then potentially massively expanding the population |
| So, yes, it's a crowded space |
Please consider a small donation if you think this website provides you with relevant information